ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616

In a recent interview with PharmaShots, Noreen Henig, Chief Medical Officer at Kezar Life Sciences shared information on clinical and pre-clinical data supporting the potential of KZR-616 to positively affect multiple drivers of immune-mediated diseases. Shots: The poster presented at ACR 2020 includes additional patient-weeks of safety and tolerability data compared to prior data presentations …

ViewPoints Interview: Kezar’ Noreen Henig Shares Insight on Therapeutic Potential of KZR-616 Read More »